Return to NG122 Overview

Lung cancer: diagnosis and management [NG122]

Measuring the use of this guidance

Recommendation: 1.2.1

Find out what the person knows about their condition without assuming a level of knowledge. Provide them with the opportunity to discuss tests and treatment options in a private environment, with the support of family members or carers (as appropriate), and give them time to make an informed choice. [2011]

What was measured: Proportion of lung cancer patients who reported being told they could bring a family member or friend with them when they were first told they had cancer.
Data collection end: June 2018
79.3%
Area covered: England
Source: Quality Health. National Cancer Patient Experience Survey.


Recommendation: 1.2.2

Ensure that a lung cancer clinical nurse specialist is available at all stages of care to support people and (as appropriate) their family members or carers.

What was measured: Proportion of people with lung cancer who were assessed by a lung cancer nurse specialist.
Data collection end: August 2018
70%
Area covered: National
Source: Royal College of Physicians. National lung cancer audit.

What was measured: Proportion of lung cancer patients who reported that they found it easy to contact their Clinical Nurse Specialist.
Data collection end: June 2018
87.4%
Area covered: England
Source: Quality Health. National Cancer Patient Experience Survey.


Recommendation: 1.2.3

Offer accurate and easy-to-understand information to people and their family members or carers (as appropriate). Explain the tests and treatment options, including potential survival benefits, side effects and effect on symptoms. [2011]

What was measured: Proportion of lung cancer patients who reported that the possible side effect(s) of treatments were definitely explained to them in a way they could understand.
Data collection end: June 2018
74.3%
Area covered: England
Source: Quality Health. National Cancer Patient Experience Survey.

What was measured: Proportion of lung cancer patients who reported that they were given the name of a Clinical Nurse Specialist who would support them through their treatment.
Data collection end: June 2018
93.3%
Area covered: England
Source: Quality Health. National Cancer Patient Experience Survey.

What was measured: Proportion of lung cancer patients who reported that, before their cancer treatment started, their treatment options were explained to them.
Data collection end: June 2018
83.8%
Area covered: England
Source: Quality Health. National Cancer Patient Experience Survey.


Recommendation: 1.2.10

Share information between healthcare professionals about: • any problems the patient has • the management plan • what the patient has been told • what the patient has understood (where possible) • the involvement of other agencies • any advance decision made by the patient. [2011]

What was measured: Proportion of lung cancer patients who reported that, as far as they know, their GP was given enough information about their condition and the treatment they had at the hospital.
Data collection end: June 2018
93.9%
Area covered: England
Source: Quality Health. National Cancer Patient Experience Survey.


Recommendation: 1.3.11

When taking samples, ensure they are adequate (without unacceptable risk to the person) to permit pathological diagnosis, including tumour subtyping and assessment of predictive markers.

What was measured: Proportion of people with stage I–II lung cancer who have a performance status of 0–1 and receive pathological diagnosis.
Data collection end: August 2018
89%
Area covered: National
Source: Royal College of Physicians. National lung cancer audit.


Recommendation: 1.4.20

For people with NSCLC who are well enough and for whom treatment with curative intent is suitable, offer lobectomy (either open or thoracoscopic).

What was measured: Proportion of people with histologically confirmed or presumed non-small-cell lung cancer who underwent surgery.
Data collection end: August 2018
18.4%
Area covered: National
Source: Royal College of Physicians. National lung cancer audit.


Recommendation: 1.4.32

Consider chemoradiotherapy for people with stage II or III NSCLC that are not suitable for or decline surgery. Balance potential benefit in survival with the risk of additional toxicities.

What was measured: Proportion of people with stage IIIA NSCLC and a good performance status who received chemotherapy and either surgery or radical radiotherapy.
Data collection end: August 2018
34%
Area covered: National
Source: Royal College of Physicians. National lung cancer audit.


Recommendation: 1.4.53

Offer people with limited-stage disease SCLC (broadly corresponding to T1–4, N0–3, M0) 4 to 6 cycles of cisplatin-based combination chemotherapy. Consider substituting carboplatin in people with impaired renal function, poor performance status (WHO 2 or more) or significant comorbidity.

What was measured: Proportion of people with small cell lung cancer who received chemotherapy.
Data collection end: August 2018
70%
Area covered: National
Source: Royal College of Physicians. National lung cancer audit.



 Return to NG122 Overview